Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 billion, respectively.

Shares of Vertex Pharmaceuticals ( VRTX -12.76%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that missed analysts’ expectations and disclosed narrower-than-expected access to its new non-opioid painkiller.